ZVRA vs. WVE, BLTE, GLPG, ARQT, INDV, AKRO, DYN, IMCR, EVO, and TVTX
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Wave Life Sciences (WVE), Belite Bio (BLTE), Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.
Zevra Therapeutics vs.
Zevra Therapeutics (NASDAQ:ZVRA) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
Zevra Therapeutics presently has a consensus target price of $21.57, suggesting a potential upside of 167.97%. Wave Life Sciences has a consensus target price of $22.22, suggesting a potential upside of 102.20%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Zevra Therapeutics is more favorable than Wave Life Sciences.
Zevra Therapeutics has higher earnings, but lower revenue than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 3 articles in the media. Zevra Therapeutics' average media sentiment score of 0.77 beat Wave Life Sciences' score of 0.54 indicating that Zevra Therapeutics is being referred to more favorably in the media.
35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Wave Life Sciences received 333 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 67.85% of users gave Wave Life Sciences an outperform vote.
Zevra Therapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.07, suggesting that its share price is 207% less volatile than the S&P 500.
Wave Life Sciences has a net margin of -66.50% compared to Zevra Therapeutics' net margin of -342.63%. Zevra Therapeutics' return on equity of -159.54% beat Wave Life Sciences' return on equity.
Summary
Zevra Therapeutics beats Wave Life Sciences on 9 of the 16 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ZVRA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ZVRA Stock Alerts